As of Q4'25 (2025-12-31), Pfizer ( PFE ) reported revenue of USD 17.56B, with year-over-year revenue growth at -1.16%. This marks a slight decrease from the previous quarter, indicating a modest contraction in top-line performance at the end of the period. From Q1'23 to Q4'25, Pfizer's revenue trend has been volatile, with significant declines in 2023—most notably a YoY drop of 54.10% in Q2'23—followed by a recovery phase in 2024, where revenue growth turned positive and peaked at 33.78% YoY in Q3'24. However, growth momentum softened in 2025, with YoY growth rates turning negative again in Q1'25 and Q3'25. Overall, the data reflects a period of sharp contraction, a strong rebound, and subsequent stabilization at a lower growth rate.